The article points to type 1 diabetes as a start.
Post# of 150296
(Total Views: 422)
Posted On: 02/14/2025 9:35:30 PM
Re: chazzledazzle #150174
The article points to type 1 diabetes as a start. I think the point is, if they (scientists) achieve success in one area, it will open the doors to any autoimmune condition and to the immune system in general. If they are successful, this direction of therapy opens the possibility of cure. Currently, the types of therapies that are either available or being explored now, offer to treat the conditions without targeting cure.
The clock is ticking means, with every delay, we run the risk of being out gunned, by ever advancing technology. This article caught my eye, because this approach, if successful, can target quite a few items on Ohm20's list of therapeutic targets for Leronlimab.
The clock is ticking means, with every delay, we run the risk of being out gunned, by ever advancing technology. This article caught my eye, because this approach, if successful, can target quite a few items on Ohm20's list of therapeutic targets for Leronlimab.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼